MET TKIs: A Comprehensive Review of Approved Treatments for MET Exon 14 Mutations

In this video, we delve into the world of MET tyrosine kinase inhibitors (TKIs) and their role in treating non-small cell lung cancer (NSCLC) with MET exon 14 mutations. We explore the different types of MET TKIs, including capmatinib, tepotinib, savolitinib, gumarontinib, and vebreltinib, and their global approval status. Discover the clinical efficacy, patient characteristics, and adverse events associated with these treatments. Learn about the unmet needs in the field, such as overcoming on-target resistance mutations and developing combination therapies. Stay updated with the latest advancements and indications for MET TKIs in China and beyond. Join us as we navigate the complex landscape of MET exon 14 mutations and the targeted therapies available.